



Côte d'Ivoire

African Region



Based on 2015 reported data



I. Epidemiological profile

Population (UN)	2016	%	Parasites and vectors			
High transmission (> 1 case per 1000 population)	23,700,000	100	Plasmodium species: <i>P. falciparum</i> (100%), <i>P. vivax</i> (0%)			
Low transmission (0-1 cases per 1000 population)	-	-	Major anopheles species: <i>An. gambiae</i> , <i>An. funestus</i>			
Malaria-free (0 cases)	-	-	Reported confirmed cases (health facility):	3,471,024	Estimated cases:	5,290,000 [3,146,000–8,660,000]
Total	23,700,000		Confirmed cases at community level:	174,057	Reported deaths:	3,340
					Estimated deaths:	7,000 [6,000–9,000]



II. Intervention policies and strategies

Intervention	Policies/strategies	Yes/No	Adopted	Antimalarial treatment policy	Medicine	Year adopted					
ITN	ITNs/ LLINs distributed free of charge	Yes	2006	First-line treatment of unconfirmed malaria	AS+AQ	2003					
	ITNs/ LLINs distributed to all age groups	No	2005	First-line treatment of <i>P. falciparum</i>	AS+AQ	2003					
IRS	IRS is recommended	No	-	Treatment failure of <i>P. falciparum</i>	AL	2003					
	DDT is authorized for IRS	No	-	Treatment of severe malaria	QN	2003					
Larval control	Use of larval control recommended	-	-	Treatment of <i>P. vivax</i>	-	-					
IPT	IPT used to prevent malaria during pregnancy	Yes	2005	Dosage of Primaquine for radical treatment of <i>P. vivax</i>	-	-					
Diagnosis	Patients of all ages should receive diagnostic test	Yes	2010	Type of RDT used	-	-					
	Malaria diagnosis is free of charge in the public sector	Yes	2012								
Treatment	ACT is free of charge for all ages in public sector	Yes	2010	Therapeutic efficacy tests (clinical and parasitological failure, %)							
	The sale of oral artemisinin-based monotherapies (oAMTs)	Is banned	-	Medicine	Year(s)	Min	Median	Max	Follow-up	No. of studies	Species
	Single dose of primaquine is used as gametocidal medicine for <i>P. falciparum</i>	No	-	AL	2012-2014	0	0	2.1	28 days	6	<i>P. falciparum</i>
	Primaquine is used for radical treatment of <i>P. vivax</i>	No	-	AS+AQ	2012-2014	0	0	2.1	28 days	6	<i>P. falciparum</i>
	G6PD test is a requirement before treatment with primaquine	No	-	Insecticide resistance tests (mosquito mortality, %)							
	Directly observed treatment with primaquine is undertaken	No	-	Insecticide class	Years	Min	Mean	Max	No. of sites	Species	
	System for monitoring adverse reactions to antimalarials exists	Yes	2011	Organophosphates	2010-2013	0.7	0.9	1	12	<i>An. coluzzii</i> , <i>An. gambiae</i> s.l., + other	
Surveillance	ACD for case investigation (reactive)	No	-	Carbamates	2010-2013	0	0.5	0.9	17	<i>An. coluzzii</i> , <i>An. gambiae</i> s.l., + other	
	ACD of febrile cases at community level (pro-active)	-	-	Organochlorines	2010-2013	0	0.2	1	18	<i>An. coluzzii</i> , <i>An. gambiae</i> s.l., + other	
	Mass screening is undertaken	-	-	Pyrethroids	2010-2013	0	0.5	1	24	<i>An. coluzzii</i> , <i>An. gambiae</i> s.l., + other	
	Uncomplicated <i>P. falciparum</i> cases routinely admitted	Yes	-								
	Uncomplicated <i>P. vivax</i> cases routinely admitted	No	-								
	Foci and case investigation undertaken	-	-								
Case reporting from private sector is mandatory	Yes	-									



III. Financing




IV. Coverage



V. Impact



Confirmed malaria cases per 1000 and ABER



Malaria admissions and deaths (per 100 000)

